Event Overview

This 3-day forum is the “must attend” event for those senior decision-makers looking to drive their medical affairs teams and departments and enhance their KOL & stakeholder engagement at all levels.

Speakers List

LARGE & MEDIUM PHARMA

Vice President Development and Chief Medical Officer
Abbvie, USA

Vice President, North America Medical Affairs Hospital Business
Pfizer

Global Medical Affairs, Excellence Head & Patient ambassador
Servier, France

Roy Gomez

Global Medical Director Endocrine & IEM
Pfizer Rare Disease, Belgium

Global Medical Director, Therapeutic Area Head, CNS & Pain
Abbott, Switzerland

EMEA Medical Lead Neurology & Immunology
Merck Group, Belgium

Director, Global Medical Excellence
Allergan, USA

Associate VP, Scientific Affairs - Operations
Accord Healthcare, UK

SMALLER PHARMA, BIOTECH & MEDTECH

Jan-Paul Rosen

Medical Affairs Oncology Director EMEA
Kyowa Kirin, UK

Head of Hearing Science and Clinical Research
MED-EL Medical Electronics, Austria

Senior Director, Medical Affairs & Operations
Voyager Therapeutics, USA

EXTERNAL STAKEHOLDERS

Member, Committee for Advanced Therapies
European Medicines Agency

Danielle Derijcke

Program Manager
The Synergist - Patient Focused Medicine, Belgium

CEO
Patient View, UK

Data Scientist
National Institute for Health and Care Excellence, UK

TECHNOLOGY COMPANIES

Customer Engineer - Government & Healthcare
Google Cloud

EXPERIENCED SOLUTION PROVIDERS

Jessica Ingram

Senior Vice President, Learning & Development
OPEN Health Medical Communications

Managing Director
Within3

President & CEO
Accreditation Council for Medical Affairs 

Helen Kane

Founder & Managing Director
ONE MSL, UK

Strategic Director
OPEN VIE

Sergio Diaz

Patient-Centred Outcomes Consultant
OPEN VIE

CEO
PharmaReview

President and Chief Science Officer
Aetion, USA

Media

CEO & Founder
PharmaPhorum, UK

Event Structure

Photo Gallery

Event Program

MedAffairs: Strategy & Capabilities

Day 1 - 3rd March, 2020

Stream Overview

The first day will feature several keynote presentations from VP-Level thought leaders on shaping and leading the medical affairs departments, justifying medical affairs performance through innovative metrics and tracking effectiveness of the function as an essential element of today’s pharmaceutical companies. They will be discussing the strategic drivers for medical affairs, and guidance on how to make best use of this vital function.

Registration & Coffee
08.30
Chairperson’s Opening Remarks
09.00

Vice President Development and Chief Medical Officer
Abbvie, USA

Effective communication: A core capability for Medical Affairs
09.10
  • How do we communicate?
  • Prioritizing communication capability in recruitment and development
  • One size doesn’t fit all - tailoring communication to your audience

Vice President, North America Medical Affairs Hospital Business
Pfizer

Integrated Evidence Plan Generation - RWD or RCT: Choosing the right tool
09.50
  • Evidence Generation requires cross functional collaboration between HEOR, Epidemiology, Value & Access, Clinical Development to name a few
  • Many tools can generate evidence to support an asset - Traditional RCT, Pragmatic Clinical Trial, Registries, Prospective or Retrospective RWD
  • Choosing the correct tool depends on a number of factors - speed, cost, complexity of data required, need for real world effectiveness or safety

Vice President Development and Chief Medical Officer
Abbvie, USA

Enhancing the medical team's role and influence in product launch
10.30
  • The ‘’commercial responsibility’’ of the medical affairs function
  • Demonstrating value for the organisation
  • recruitment and training today and tomorrow

EMEA Medical Lead Neurology & Immunology
Merck Group, Belgium

Networking & Coffee Break
11.10
Demonstrating the value of Medical Affairs to internal & external stakeholders
11.40

Global Medical Director, Therapeutic Area Head, CNS & Pain
Abbott, Switzerland

Panel discussion: The impact of internal stakeholders on Medical Affairs capabilities development
12.20
  • Managing cross functional teams i.e. clinical/ regulatory/commercial /market access.
  • Which skills are required from medical affairs professionals today in order to co-operate with internal stakeholders?
  • Unique medical affairs HR plans for talent recruitment and retention.

Vice President Development and Chief Medical Officer
Abbvie, USA

Vice President, North America Medical Affairs Hospital Business
Pfizer

Global Medical Director, Therapeutic Area Head, CNS & Pain
Abbott, Switzerland

President & CEO
Accreditation Council for Medical Affairs 

Jessica Ingram

Senior Vice President, Learning & Development
OPEN Health Medical Communications

Luncheon Break
13.00
Which skills are required from Medical Affairs professionals today?: Retooling your team to maximise performance
14.00
Jessica Ingram

Senior Vice President, Learning & Development
OPEN Health Medical Communications

Patient engagement training for industry professionals
14.30
Danielle Derijcke

Program Manager
The Synergist - Patient Focused Medicine, Belgium

Leveraging online discussion platforms for optimal insight generation & stakeholder engagement
15.00
  • Identify the logistical and resource barriers to domestic and global stakeholder engagement & insight retention
  • Learn about innovative communication solutions that leading organizations utilize to overcome these challenges and drive value-added insight development.
  • Discuss how to use these solutions to deliver improved engagement outcomes while maintaining regulatory compliance

Managing Director
Within3

Networking & Coffee Break: Sponsored by Within3
15.30
Designing and implementing training programs for Medical Affairs professionals
16.00

President & CEO
Accreditation Council for Medical Affairs 

Associate VP, Scientific Affairs - Operations
Accord Healthcare, UK

How Medical Affairs can break the mold in capability deployment: Copy review in action @ PharmaReview
16.30

CEO
PharmaReview

Panel discussion: Optimising cooperation with external stakeholders: Understanding their expectations and requirements
17.00
  • Understanding external stakeholders’ new requirements.
  • How can the pharma industry satisfy them all?
  • How does this affect medical affairs goals, definitions and structure?
Danielle Derijcke

Program Manager
The Synergist - Patient Focused Medicine, Belgium

CEO
Patient View, UK

Managing Director
Within3

Chairperson’s closing remarks
17.40
End of day one
17.50

19.00 Networking Dinner

MedAffairs: Real-World Evidence

Day 2 - (AM) - 4th March, 2020

Stream Overview

Generating real world evidence via observational studies and the use of patient registries is one of the fastest growing areas of pharmaceutical R&D. Such post-marketing studies are becoming increasingly important as regulatory agencies demand more long-term data which demonstrates efficacy, safety and quality. The Medical Affairs unit plays a decisive role in generating this vital evidence and this stream will present solutions to the challenges companies face in generating high-quality evidence which will communicate a compelling value argument to all necessary stakeholders.

Registration & Coffee
08.30
Chairperson’s opening remarks
09.00

CEO & Founder
PharmaPhorum, UK

The value of real-world data to patients and prescribers: A case study
09.10
Roy Gomez

Global Medical Director Endocrine & IEM
Pfizer Rare Disease, Belgium

Digital approaches to using ML for de-identification of patient data, enrichment of data using Natural Language Processing and cloud search.
09.40

We live in a world where researchers, healthcare providers, pharmaceuticals collaborate more closely than they used to. Collaboration requires information sharing and this brings the challenge of ensuring sensitive information is not shared. In Google Cloud, we have used ML approaches to build tools for de-identification of data, NLP and search to make finding information a little easier.

Customer Engineer - Government & Healthcare
Google Cloud

Identifying when and where real world evidence (RWE) can provide credible evidence of treatment effect
10.10
  • Leading insights on the role of RWE in regulatory decision-making
  • Lessons from inside the FDA's RCT-DUPLICATE demonstration
  • Implications for Medical Affairs planning and key decision makers

President and Chief Science Officer
Aetion, USA

Networking & Coffee Break: Sponsored by ACMA
10.40
Considerations for evidence generation early in the product development process
11.10

Strategic Director
OPEN VIE

Sergio Diaz

Patient-Centred Outcomes Consultant
OPEN VIE

HTA PERSPECTIVE

Transforming health and social care guidance with ‘real world’ evidence: Initiatives at NICE
11.40

Data Scientist
National Institute for Health and Care Excellence, UK

Panel discussion: Leveraging real-world evidence to make a meaningful difference to your product value
12.10
  • Demonstrating the ROI of RWE to internal stakeholders.
  • Strategies for small/medium pharma to generate RWE on limited budgets.
  • Motivating academically-focused investigators for commercially-focused studies.
  • Incorporating HEOR endpoints into Phase III and IV studies.
  • Integrating IIT into your post-marketing development strategy.
  • The increasing impact of eHealth, AI and big data.
Roy Gomez

Global Medical Director Endocrine & IEM
Pfizer Rare Disease, Belgium

Strategic Director
OPEN VIE

President and Chief Science Officer
Aetion, USA

Data Scientist
National Institute for Health and Care Excellence, UK

Luncheon Break
12.40

MedAffairs: Communications & Liaison

Day 2 - (PM) - 4th March, 2020

Stream Overview

Medical Affairs departments are increasingly looking to implement next generation medical communication practices, to offer essential evidence-based information to stakeholders on demand, through a variety of classical, yet also increasingly digital channels. This stream will focus on two key aspects of medical communication. Firstly, issues such as: protocol writing for internal late-phase studies and research initiatives; working with External Experts (KOLs) to enhance publications, abstracts & posters and receiving proposals for investigator-initiated studies. The second section of this day will focus on Medical Scientific Marketing communications, including the review process, compliance issues, ensuring the claims made by marketing colleagues are justified and appropriately communicated and also effectively localized from global-level to country-level market requirements. The day will also feature best practice case studies on structuring, managing, and monitoring the evolving Medical Science Liaison role within your organisation. This meeting is an ideal chance to benchmark with other market leaders in this field who are utilising the unique MSL function to more effectively communicate with external experts, engage them with advanced science and demonstrate product evidence. All attending will discovery how MSLs can help regain the credibility of the pharmaceutical industry as a value-adding partner to the healthcare ecosystem.

MEDICAL COMMUNICATION: MULTI-STAKEHOLDER’S NEEDS

How to improve drug-treatment information?: What do patients expect from pharma?
13.30

CEO
Patient View, UK

The impact of digitalisation on medical communications
14.00

CEO & Founder
PharmaPhorum, UK

Networking & Coffee Break: Sponsored by Open Health
14.30

NEXT GENERATION MSL MANAGEMENT

Global medical excellence: Empowering high-performing MSL teams
15.00
  • Global medical excellence - A key partner driving medical excellence & value
  • Key opinion leader engagement & insights for MSLs, a value driver for medical affairs
  • The medical science liaison role in launch excellence - Ready, Set, Launch!

Director, Global Medical Excellence
Allergan, USA

Building best-in-class MSL functions for the 21st century healthcare industry
15.30
Helen Kane

Founder & Managing Director
ONE MSL, UK

Panel discussion: Next-generation MSL capability development
16.00
  • Which new capabilities are required from MSLs today and will be in the future?
  • What has to change internally to enable MSL success?
  • The emerging importance of health outcomes liaison.
  • Capabilities and reskilling training.

Vice President, North America Medical Affairs Hospital Business
Pfizer

CEO & Founder
PharmaPhorum, UK

Helen Kane

Founder & Managing Director
ONE MSL, UK

Chairperson’s closing remarks
16.40
End of day two
16.50

MedAffairs: Effectivness for Small Pharma & Medtech

Day 3 - (AM) - 5th March, 2020

Stream Overview

  • Building an effective, medical affairs team with limited resources, that adds-value to external stakeholders
  • Determining what capabilities, skills, resources and team structure is realistically required to maximise performance
  • Cultural change: Transformation to a patient and stakeholder-centric organization, that is science-led
  • Maximisation of real-world evidence generation on limited budgets
  • Leveraging both classical and digital medical communication strategies with a small team to maximise dialogue with KOLs and stakeholders
  • Demonstrating the value of medical affairs to internal stakeholders
Registration & Coffee
08.30
Chairperson’s Opening Remarks
09.00

Senior Director, Medical Affairs & Operations
Voyager Therapeutics, USA

The value of patient registries for patients, regulators and manufacturers
09.10

Member, Committee for Advanced Therapies
European Medicines Agency

Which unique skills are required from Medical Affairs professionals in smaller pharma companies?
09.50
Jan-Paul Rosen

Medical Affairs Oncology Director EMEA
Kyowa Kirin, UK

The ideal department structure to support regulatory approval and considering HTA requirements
10.30
  • The impact of limited budgets on skill development
  • Medical affairs commercial responsibility in a smaller operation
  • Closing the gap between regulatory and reimbursement requirements: How should the industry get prepared?

Head of Hearing Science and Clinical Research
MED-EL Medical Electronics, Austria

Networking & Coffee Break: Sponsored by MedAffairs Hub
11.10
Building Medical Affairs from the ground up
11.40
  • Establishing the need for Medical Affairs in an early-stage biotech
  • Additional Medical Affairs needs in rare and gene therapy
  • Building and maintaining value

Senior Director, Medical Affairs & Operations
Voyager Therapeutics, USA

Panel Discussion: Capabilities development for smaller Pharma, Biotech & MedTech
12.20
  • What is the ideal role of the medical affairs department today in a dynamic cross-functional team?
  • How to build a high-performance team with limited resources?
  • Establishing communications and new value-adding relationships.
  • Ideal department structure and reporting lines in smaller corporations.
  • Demonstrating the value of Medical Affairs to internal stakeholders in a smaller organisation.
Jan-Paul Rosen

Medical Affairs Oncology Director EMEA
Kyowa Kirin, UK

Head of Hearing Science and Clinical Research
MED-EL Medical Electronics, Austria

Senior Director, Medical Affairs & Operations
Voyager Therapeutics, USA

Luncheon Break
13.00

MedAffairs: Persuasion & Influence Skills

Day 3 - (PM) Training Workshop - 5th March, 2020

Stream Overview

Essential tactics to engage and understand stakeholders, influence them and communicate value-adding solutions
 
This is a unique, training course specifically tailored towards life science professionals, who are motivated to engage KOLs and external stakeholders, influence colleagues, stand out from the competition, overcome objections and better articulate the true value of their solutions.
 
What's the unmet need?
We at NextLevel Life Sciences, have a unique perspective on how life science professionals can dramatically and immediately improve their influence & persuasiveness. At our pharma and medtech industry events, we constantly observe our clients’ successful interactions, but also missed opportunities. For example, many executives in life sciences companies are true subject-matter or technical experts. Often, however, they haven't received any structured training on influence, persuasion, negotiation or “sales skills”, so are not maximising their chances of ensuring the most from each customer interaction.
 
We have recognised a strong need for a structured and interactive course which will definitely help medical and clinical affairs professionals to engage stakeholders, appreciate their needs, positively influence them, demonstrate true value and forge lasting business relationships.

Who are your trainers?

Geoff Cable                               
CEO & co-Founder                         
NextLevel Life Sciences
 

Luke Rogers
CEO & co-Founder
NextLevel Life Sciences


"We believe that persuasion isn't a job, it's a life skill"

Geoff and Luke are experts in soft skills, negotiation, business development, management & entrepreneurship. They have a strong track record of growing their successful company organically, through sales and marketing. Both are Australians and also CEOs and co-founders of NextLevel Life Sciences, a leading event organiser and business intelligence provider for the Biopharma and Medtech industries. Over the last 12 years, Luke and Geoff have developed, promoted and delivered hundreds of industry events, focused on cutting-edge or critical themes. These have involved thousands of senior-level attendees from all the major pharma, medtech, biotech and diagnostics companies, as well as a broad range of service providers and key industry stakeholders. NextLevel Life Sciences has a strong value proposition, an effective process, but especially a customer-centric sales philosophy.

Building magnetic rapport: Making the most out of your customer interactions
14:00
  • How to quickly engage people and avoid awkwardness
  • Striking up conversations
  • Verbal & non-verbal communication for maximum impact
  • Role Play: Initial Engagement at Congresses & Business Situations
Identifying Needs through powerful Questioning & Listening
14.30
  • Why are most people bad listeners?
  • Directed questions to help you achieve your outcomes
  • Quickly defining your customer’s needs
Break
15.00
Identifying Needs through powerful Questioning & Listening (continued)
15.20
  • Activity: Active listening in action
  • Role Play: Diagnosing Needs
How to be more persuasive & What to do when you hear "No"
15.40
  • Best practice steps to handling objections
  • Gently challenging your customer to think differently via smart questions
  • Storytelling as an emotional persuasion tool
  • Minimising the perceived risk vs your strong value proposition
  • Understanding why the partner is saying "No"
  • Activity: Developing a customized objection handling roadmap for your product/service
  • Activity: Developing storytelling for your common & expected objections
  • Role Play: Negotiation & Objection Handling with Stakeholders
 
Closing remarks
17.00
End of day 3
17.10

This event will enable you to:

1) Understand how medical affairs are at the forefront of new pharmaceutical industry commercial models and what needs to be done to maximise success.
2) Discover which are the most intelligent ways to map and engage with KOLs and other prescribers, payers, patient groups, pharmacies and tomorrow’s stakeholders.
3) Measure the performance of your medical affairs team and individuals.
4) Benchmark with experts to find out the best practices in late phase research, especially observational studies, patient registries and investigator-initiated studies.
5) Discover how medical scientific liaisons, in support of commercial teams, are crucial to the communication of effectiveness, safety and cost effectiveness.
6) Get real-life experiences of medical affairs capabilities development in smaller Pharma, Biotech & MedTech companies.

PHARMA & MEDICAL DEVICE: VPs, Directors & Managers of:
Customer Relations, Medical Affairs, Medical Science Liaisons, Medical Education, Health Outcomes & Liaison, Medical Communications, Marketing, KOL & Stakeholder Engagement, Late Phase & Real-World Research, Scientific Affairs, Medical Advisors and Patient-Centricity.

Event Partners

This event is accredited for CPD (Continuing Professional Development) status

RECEIVE DISCOUNTED FLIGHTS WHEN YOU REGISTER FOR THIS EVENT WITH

Speaker Biographies

Rob Scott

Vice President Development and Chief Medical Officer
Abbvie, USA

Dr Rob Scott is Zimbabwean born and a graduate of University of Cape Town. Rob has held leadership positions in global Pharma for over thirty years. At Pfizer he developed Lipitor and Norvasc, including personal involvement in many large scale CV trials. At AtheroGenics, he designed and implemented the first large cardiovascular outcomes study to be wholly performed by a small biotech. At Amgen, Rob conducted the first outcome study for a PCSK9i, FOURIER. Rob was a member of the FDA Cardiac and Renal Drug Advisory Committee from 2012 to 2016. Rob is currently the Chief Medical Officer at Abbvie with responsibility for around 40 new molecular entities, four thousand people and a budget of close to three billion dollars. He also created the Development Design Center, a Center of Excellence focused on using predictive analytics and big data to design and implementing clinical trials. He is a board member of Transcelerate and a member of the PhRMA R&D Leadership Forum. Rob is a leader in digital transformation of clinical research.

Eddie Power

Vice President, North America Medical Affairs Hospital Business
Pfizer

Eddie Power PhD MBA is currently the VP, North America Medical Affairs, Hospital Business at Pfizer and has held positions of increasing responsibility during his career in the pharmaceutical industry.

He started at Pfizer in September 2010 leading US teams in Vaccines and Infectious Diseases before assuming before assuming US Medical Affairs leadership for Pfizer’s Essential Health business Unit. Before joining Pfizer, Eddie held Medical and Clinical Development positions at Cubist, Bayer and GSK.

He has a passionate interest in learning and capability development for Medical Affairs colleagues and teaches for the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) Academy/Kings College Medicines Development Certification Program.

Before joining the pharmaceutical industry, Eddie held a faculty position at United Medical and Dental Schools, Guy’s & St Thomas’ Hospitals, London, UK. He holds a PhD degree from the Welsh School of Pharmacy, University of Wales, UK and an MBA from Henley Management College, UK

Dan Atlan

Global Medical Affairs, Excellence Head & Patient ambassador
Servier, France

Dan Atlan, MD, is currently working in global medical affairs (GMA) in Servier. Dan is passionate in Medical Affairs over 16 years, typically cross functional leadership, launch preparation activities and set up of new structures or team integration following acquisitions. In 2016, he set up the first GMA team in this company starting with Oncology area and has set up the first GMA cross TA excellence unit. Previously, Dan worked in Novartis oncology and Janssen for various roles in medical affairs, from local to global positions, specifically in oncology. Originally, Dan is a clinical oncologist, trained in France and has practiced in academic hospitals over a decade.

Pascal Dowling

Global Medical Director, Therapeutic Area Head, CNS & Pain
Abbott, Switzerland

A British national with a clinical pharmacology degree from the University of Manchester (UK), an MPhil in Neuroscience from Cardiff University (UK), and PhD in Neuroscience/Neuropharmacology from the Georg-August-University Gottingen (Germany) together with the University Medical Centre Goettingen, and Max-Planck institutes for experimental medicine and Biophysical Chemistry, working on the topics of movement disorders, myelin research, human stem cell research for Parkinson’s, and models of Alzheimer’s disease. Afterwards a post-doctorate was obtained in Pharmacology from the Max-Planck Institute for Heart and Lung Research Bad Nauheim (Germany) working on orphan GPCRs.                                                                                                                    Initially, I worked in ICON a clinical research organization, later entering the consumer/FMCG industry as medical marketing manager for L’Oreal Germany, leading medical consumer marketing initiatives in dermatology and nutrition (with Nestle) across Germany, Austria and Switzerland. Later, joining the pharmaceutical industry as international associate medical director for Gruenenthal Pharmaceuticals, managing products in chronic pain across EU+ regions. Afterwards, I made the move to rare diseases and worked at Shire Pharmaceuticals in Switzerland as global associate director of medical communications for genetic diseases (Fabry and Gaucher disease), and HAE. My current position is Global Medical Director and therapeutic area head of CNS & Pain at Abbott across the emerging markets and responsible for all pipeline and mature product programs. Amongst other things, my passion is neuroscience and improving global mental health.

John-Kenneth Sake

EMEA Medical Lead Neurology & Immunology
Merck Group, Belgium

John-Kenneth holds a medical degree from the University of Antwerp in Belgium where he also obtained a MBA degree.

He has been working in the Bio-pharmaceutical industry since 1993 in various roles with a country, European and global perspective leading large virtual teams, driving organizational change processes and being involved directly in 5 major launches. He has been Medical Director in Belgium, the Netherlands and the UK, was global medical affairs franchise lead and afterwards European medical affairs Neurology lead at UCB, before joining Merck KGaA in January 2017. 

John-Kenneth is passionate for translating scientific data into patient solutions through intensive collaboration with both internal and external stakeholders. As a former patient himself he experienced the importance of innovation, communication, transparency and collaboration between stakeholders to optimize individual patient outcomes. 

Tonya Johnson

Director, Global Medical Excellence
Allergan, USA

I have a 34 year diverse career in the pharmaceutical industry.  I received my Doctorate of Pharmacy degree from Rutgers University. I started my career at Lerderle Labs (Pearl River, NY) cross-training in various roles including Quality Control/Validation Specialist, Sr. Formulations Researcher, Sr. Chemistry, Manufacturing & Control (CMC) Regulatory Affairs Manager and Production Supervisor leading 25 Union Operators in Manufacturing & Production.  After my diverse 10 year career with Lederle, I broadened my experience working at  Warner Lambert/Parke Davis as a Senior Clinical Research Associate and subsequently joined Schering Plough as Sr. Manager, Regulatory Affairs.  I joined Allergan in 2002 increasing my depth and breadth of experience as a Medical Science Liaison (MSL), Sr. MSL, East Region MSL Peer Leader, National Director, Neuroscience MSL Team (2013) and most recently Director, Global Medical Excellence since 2016.

Eric Bouilloux

Associate VP, Scientific Affairs - Operations
Accord Healthcare, UK

Over the last 24 years, Eric has gained fundamental life science and pharmaceutical industry experience covering Drug Development, Medical Affairs, Alliance Management and External Innovation.

Eric started his pharmaceutical career back in 1996 in France before moving to the UK in 1997 at a time where the EMA established itself at Canary Wharf and the Bristish biotech business was booming.

From clinical research management to global cross-functional drug development leadership, he has led many early stage to life cycle management product development in a variety of therapeutic areas such as oncology, gastro-enterology, bone health, inflammation, CNS, neurosciences.

Opportunities took him through a range of companies from virtual biotechs (SR Pharma, spinoff from UCL) to small & mid-size pharmaceutical entities (Norgine, Ipsen), to larger organisations such as Amgen.

Although Eric takes pride of being capable to “kill products quickly” as they appear not to be able to deliver the promise of the 4 hurdles (safety, efficacy, quality, access), Eric also achieved to deliver products to the market as he led the successful registration, approval and launch of 3 Biological License Applications in the US and equivalent in European/Worldwide markets…this being for adult and paediatric populations. To Eric, the ability to help and serve patients including children, providing them with beneficial treatment solutions and some relief to their debilitating condition is the most rewarding achievement.

With that strong track record, Eric embarked in an executive role at Ipsen Global Medical Affairs, reporting to the CMO, building the infrastructures & capabilities, as well as overseeing its execution.

More recently, Eric joined Accord Healthcare as Associated VP, Scientific Affairs – Operations, where he provides medical affairs leadership to the portfolio’s strategy and operational execution in the EMENA region.

Severin Fürhapter

Head of Hearing Science and Clinical Research
MED-EL Medical Electronics, Austria

Severin Fürhapter holds a master’s degree in Physics obtained at the University of Innsbruck, and a PhD in Medical Sciences from the Innsbruck Medical University. He started his career as Scientific Research Assistant at Innsbruck Medical University in 2004. In 2008, he joined Vibrant MED-EL’s Clinical Support and gained profound clinical expertise in supporting medical devices throughout their lifecycle. Severin was promoted to the Head of Hearing Science in 2011, focusing on health technology assessment and reimbursement activities. Since 2013 he is Head of Hearing Science and Clinical Research at MED-EL, Business Unit Vibrant. His responsibilities cover all aspects of Clinical Research, Health Technology Assessment and Applied Hearing Science, looking both on clinical parameters of several product lines and their reimbursement in a cross-functional department.

Elisabeth Fine

Senior Director, Medical Affairs & Operations
Voyager Therapeutics, USA

With 20 plus years of progressive leadership in academia, biotech, and consulting, Elisabeth has led the Medical Affairs function at Voyager Therapeutics, Inc since its inception. She brings to her current role a track record of building cross-functional, long-term, patient-focused strategies in Medical Affairs and Communications and the operational infrastructure to support their successful implementation. Throughout her biotech career she has developed deep experience in Medical Affairs strategy and tactics, Commercial and payer communications, and Regulatory Affairs, and has launched drugs in the US, EU, and around the world, supporting Medical Affairs, Regulatory Affairs, and Commercial. Elisabeth is a Visions Scientist by training, and prior to joining biotech was on the faculty of the Schepens Eye Research Institute/Harvard Medical School.

Kieran Breen

Member, Committee for Advanced Therapies
European Medicines Agency

Dr Kieran Breen is currently Head of Research and Development at St Andrew’s Healthcare which is a secure mental health facility with accommodation for over 850 patients. He has expertise in the development of multi-disciplinary research initiatives including the establishment and utilisation of patient clinical data registries. In collaboration with the US Critical Path Institute, he established a Parkinson’s Disease data registry initiative involving participants from academia, industry, regulatory bodies and patient groups. He is a member of the European Medicines Agency Committee for Advanced Therapies where he also serves on the cross-Committee working group on patient data registries. As a member of the EMA Patients and Consumers Working Party, he has liaised closely with the public on the use of clinical data in the development of clinical trials and post marketing medicines monitoring.

Alex Wyke

CEO
Patient View, UK

Alex Wyke is CEO and founder of PatientView, a UK-based research, publishing and consultancy group. PatientView has worked to build bridges worldwide with the health NGOs that comprise the patient movement, to help define and support one of the most important phenomenon changing healthcare in the 21st Century. (For more on PatientView, see: www.patient-view.com). PatientView is the publisher and owner of the series Corporate Reputation of Pharma – from a patient perspective, Benchmarking the patient Movement as well as the online mhealth resource for public and patients, myhealthapps.net.

From 1996 to 2000 Alex was responsible for creating and running the international healthcare publishing unit at The Economist Intelligence Unit. She was previously business and science correspondent for The Economist.

Thomas Lawrence

Data Scientist
National Institute for Health and Care Excellence, UK

I've only been at NICE for 6 months, but prior to that I worked at the University of Manchester for 10 years, primarily with the Trauma Audit & Research Network - a group that collects real world data about patients that have suffered from severe trauma in the UK and Ireland. There I gained extensive experience in assessing the quality of and gaining insights from real world data.

Hariprasad Radhakrishnan

Customer Engineer - Government & Healthcare
Google Cloud

Hari is a customer engineer at Google Cloud with a focus on Life Sciences, genomics and Biotech. He spent more than fifteen years in technology roles helping customers drive value from data across Pharmaceutical, Healthcare, Biotech and other sectors before joining Google Cloud.  At Google, he is focused on making Cloud and ML accessible to enterprises, start-ups, and researchers, to drive innovation and growth.

Andy Bowman

Managing Director
Within3

Andy is a healthcare communications specialist with over 30 years of experience within the global pharmaceutical and biotechnology sectors and has the responsibility of leading the partnership efforts for Within3 in Europe.

Andy started his pharmaceutical career as a medical representative in the UK with Glaxo, progressing within the industry through training, sales management and marketing before leaving the client side of the business to take up senior roles in advertising, PR, sales promotion, direct marketing, clinical research, medical education and communications.

Throughout his career Andy has been passionate about strengthening the bond between the patient and the HCP and as a consequence he has worked extensively with patients, PAGs and medical societies in Parkinson’s disease, HIV and AIDS, Crohn’s Disease, Diabetes, transplantation and COPD. Most recently Andy has been working in ankylosing spondylitis and psoriatic arthritis to help accelerate the patient journey towards effective treatment and improving the dialogue between the patient and physician.

Andy is a certified medical publications professional (CMPP) and a Practitioner at the Association for Business Psychology

William Soliman

President & CEO
Accreditation Council for Medical Affairs 

An experienced senior executive with several years of experience in the Pharmaceutical & Biotechnology industry, Dr. Soliman has held key positions where he was instrumental in launching a variety of innovative platforms in medical affairs. He speaks frequently regarding the ever changing role of medical affairs at major medical affairs conferences. He currently the Executive Chair, President on the board of the Accreditation Council for Medical Affairs (ACMA) whose primary mission is to create industry standards and goals for medical affairs professionals.

He has held several management roles across the industry within medical affairs such as at Retrophin, Eisai, Gilead Sciences, Abbott Laboratories, Boehringer-Ingelheim, and Merck.  Dr. Soliman previously also served as Vice President of Medical & Scientific Affairs at CME LLC, a leading provider of CME to health care providers nationwide. He also has worked on the strategic management consulting side with companies such as Veeva systems, and is often brought in as a subject matter expert on medical affairs for healthcare investment and advisory firms. 

He has published extensively & led a number of initiatives focusing in the areas of ischemic heart disease, dyslipidemia, diastolic heart failure, type 2 diabetes, and obesity where he has collaborated with some of the nation's top research institutions such as the Pennington Biomedical Research Center, the Washington Center for Weight Management & Research, the Yale School of Medicine Digestive Diseases Program and the University of Pennsylvania's Center for Weight & Eating Disorders.  Dr. Soliman was most recently invited to speak at the Center for Medical Technology & Policy's (CMTP) conference on Comparative Effectiveness Research to help inform payers, healthcare policy makers, physicians and patients on the most effective ways to design clinical trials to better address gaps in medicine. He also recently presented at the 2014 annual American Diabetes Association (ADA) Conference on preventing the progression of type 2 diabetes among pre-diabetic overweight and obese individuals. In 2008, Dr. Soliman published a book entitled The Rise of Chemistry: Implications for Industry & Education. 

Dr. Soliman is featured in the media and news often for his perspective and views on the evolving role of medical affairs/MSLs in the pharmaceutical industry. He has been featured in Forbes, the Pharmaceutical Executive, ABC News, the Pharmacy Podcast, and most recently on Relentless Health Value with well-known host Stacey Richter who focused on healthcare thought leaders. 

 

He has also held several academic appointments at Seton Hall University's School of Health & Medical Sciences, New Jersey City University, Kean University's College of Natural & Applied Sciences, and Touro Colleges of Osteopathic Medicine, Pharmacy & Physical Therapy teaching a variety of courses including clinical therapeutics, pharmacology, pathophysiology, and epidemiology. 

Dr. Soliman earned his PhD, MPhil from Columbia University, his Bachelor’s degree from New York University and a Masters Degree from St. Peter's University. He completed post-doctoral training at Harvard University’s T.H Chan School of Public Health. 

Amanda Pulfer

Strategic Director
OPEN VIE

Amanda Pulfer is Joint Managing Director at pH and manages the team of RWE consultants responsible for the design of robust Real World Evidence solutions to meet the needs of our pharmaceutical industry clients and NHS collaborators.  Amanda has more than 10 years’ experience in RWE consultancy and works with clients to develop robust 3-5 year RWE plans to support their portfolios through interactive facilitated workshops. Prior to joining pH Associates Amanda worked in the pharmaceutical industry for more than 10 years’ in a variety of roles in sales and marketing.  She brings to pH first-hand experience of the challenges faced by pharmaceutical companies and an understanding of the complexity involved in overcoming these whilst meeting NHS needs.  Amanda has a degree in Natural Sciences from Cambridge University (Part II Molecular Cell Biology) and completed a postgraduate Diploma in Marketing from the Chartered Institute of Marketing

Tessa Pugh

CEO
PharmaReview

Tessa graduated with a degree and professional diploma in Strategic Marketing in the early 1990s. Her formative years were spent in client facing roles at advertising agencies, including Saatchi and Saatchi and FCB in London, where she looked after Financial Services and FMCG clients. Tessa launched PharmaReview 7 years ago, with Dr Ralph Carter.  PharmaReview is a   specialist provider of outsourced copy review services to the pharmaceutical industry.  Its  mission is to reduce the time and cost which internal copy review places on senior members of  clients’ medical, regulatory and commercial teams while maintaining the highest levels  of regulatory adherence and compliance. Tessa is a highly experienced practitioner in ZincMAPS and Veeva Vault PromotMats functionaility and a copy review process expert.

Jeremy Rassen

President and Chief Science Officer
Aetion, USA

Jeremy A. Rassen, MS, ScD is a pharmacoepidemiologist with 25 years of academic and industry experience.  He is co-founder, president, and chief science officer at Aetion, a health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. He also worked in Silicon Valley in a variety of tech companies.  Dr. Rassen received his bachelor’s degree in Computer Science from Harvard College and his master’s and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.

 

Jeremy A. Rassen, MS, ScD is co-founder, president, and chief science officer at Aetion, a health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies. Prior to founding Aetion, Dr. Rassen was Assistant Professor of Medicine at Harvard Medical School, where he focused on methods to improve the quality and validity of real-world data studies. He also worked in Silicon Valley in a variety of tech companies.  Dr. Rassen received his bachelor’s degree in Computer Science from Harvard College and his master’s and doctorate degrees in Epidemiology from the Harvard T.H. Chan School of Public Health.

Paul Tunnah

CEO & Founder
PharmaPhorum, UK

Dr Paul Tunnah founded pharmaphorum in 2009, which combines industry leading

publications (www.pharmaphorum.com) with a specialist strategy and content communications / marketing consultancy (www.pharmaphorumconnect.com). All aspects of his work at pharmaphorum align around the company’s vision of ‘bringing healthcare together’ – ensuring all stakeholders have a voice and can collectively engage to find mutually beneficial solutions.

He is a recognised author, speaker and industry advisor on content marketing, communications and digital innovation, having worked with many of the world’s leading pharmaceutical companies and the broader ecosystem of healthcare organisations. He is also a member of the steering committee for Frontiers Health, a leading event on digital disruption in healthcare, attended by industry, start-ups and investors.

Dr Tunnah has a scientific background, with a BA in Biochemistry and DPhil in Biological sciences, focussed on development of novel anticancer therapies, from Oxford University.

Connect with Dr Tunnah at https://www.linkedin.com/in/paultunnah/ or email paul.tunnah@pharmaphorum.com.

Previous Attendees at MedAffairs Leaders Forum - Zurich, Switzerland, 2019

Company
Job Title
Alcon
Medical Director
Alexion
Medical Affairs Manager
Alexion
MEDICAL AFFAIRS MANAGER PNH
Almirall
Neurology and other products Medical Manager
Angelini Farmaceutica, Lda
Medical Director
Ashfield Healthcare
International Business Development Executive
Bayer Business Services
Head IT BP Research & Development
Bayer Business Services
Digital Health Innovation Manager
Bayer Business Services GmbH
IT Business Partner Medical Affairs & Pharmacovigilance
BIOCAD SK
Medical Affairs Director
Boehringer Ingelheim
Head Regional Medical Affairs
Bristol-Myers Squibb
Medical Strategy, Operations and Governance Lead
Bristol-Myers Squibb
Field Medical Lead
Bristol-Myers Squibb
Oncology Medical Lead
Bristol-Myers Squibb
Disease Area Specialist
BTG International
SVP Head Clinical Development
Celgene
Director, Biostatistics
Celgene AB
Nordic Medical Director
Celgene AB
Nordic Assoc. Medical Director
Center for Research and Interdisciplinarity (CRI)
Managing Director
Complete HealthVizion
Global Head
Complete HealthVizion
Medical Affairs Director
Covance
Senior Director
Covance
Director
CSL Behring
Associate Director Medical Affairs
Daiichi Sankyo
Medical Affairs Manager Nordics
Eli Lilly
Sen. Director Operations & Capabilities International Medical Affairs
Eli Lilly
Therapeutic Area Leader Diabetes, International Medical Affairs
Eli Lilly
Sen. Medical Director UK Hub
Erytech
Head of Medical Affairs
European Medical Association (EMA)
President
Ferring Pharmaceuticals
Chief Medical Officer, Surgical Products & Exogen
Gelesis
Vice President, Medical Affairs
GSK
Strategic Capability Director
Helsinn Healthcare
Medical Affairs Manager
Hexal AG
Global Medical Manager
Hologic
Head of Scientific Affairs
ICTA PM
Business Development
Ipsen Pharma
Head of Global Medical Information
IPSEN Pharma
Global Medical Information Manager - Oncology
IQVIA
Senior Principal Head of Real World Insights, UK & Ireland
Italfarmaco
Medical Director
Janssen
Medical Advisor
Janssen
Medical Scientific Liaison
Janssen
Director of Medical & Regulatory excellence
Janssen
S. Director Medical Excellence Hub EMEA
Janssen, Pharmaceutical Companies of Johnson and Johnson
MSL Manager
Kyowa Kirin
International Medical Affairs Consultant
Kyowa Kirin Pharma
Medical Director CEEMERIT
Kyowa Kirin Pharma
Medical Affairs Manager
Kyowa Kirin Services Ltd.
Medical Director
Maquet Cardiopulmonary Gmbh
Clinical Manager
McCann Health Medical Communications Ltd
Scientific Division Lead
McKinsey and Company
Partner
MD squared
Managing Director
Merck Group
EMEA N&I Medical Affairs Director
Monocl
Sales Director
Norgine
VP, Medical Affairs
Novartis Oncology
Medical Excellence Director, Region Europe
OM Pharma
Medical Affairs Associate
OPEN Health
Account Director
OPEN Health
Principal Consultant Patient Centred Outcomes
OPEN Health Medical Communications, UK
Account Director
Otsuka Pharmaceuticals
Senior Medical Director US Medical Affairs – Neuroscience
PatientView
Founder & CEO
PatientView
Editorial director
Pfizer
Medical Director, EMEA
Pfizer, USA
Senior Director, Enterprise Benefit Risk Medical Director Worldwide Medical and Safety | Global Medical Impact Assessment
PharmaReview
Director
Pharming Group
Vice President Medical Affairs
Philips
Senior Director, Global Medical Science Liaison
Pinnacle Wellbeing 247
CEO, Head of Clinical Services, Senior Executive Coach
Prescient Healthcare Group
President
Prescient Healthcare Group
Senior Vice President
RBW Consulting
Associate Director
RBW Consulting
Account Manager
RBW Consulting
Head of Global Talent Strategy
Rhythm Pharmaceuticals
Senior Manager Medical Communications
Roche
Medical Manager
Roche
International Medical Affairs Manager Critical Care
Roche Diagnostics
Head Medical Affairs, Global Medical and Scientific Affairs CPS
Roche Diagnostics International
International Medical Manager
Sanofi Genzyme
Vice President, Global Medical Affairs Head, Respiratory
Sorin Group Italia
Director Medical Education and Scientific Liaison
Sorin Group Italia
Global Medical Education Manager
Syneos Health
Director, Consulting
Syneos Health
Syneos One Specialist
Syneos Health
Principal, Real World and Late Phase
Syneos Health, UK
Project Specialist, Real World & Late Phase and Syneos One
Teleflex
Clinical Manager
Teva Pharmaceuticals
Medical Director, Region Europe, MSL and Digital Transformation
UCB
Vice President and Head of External Engagement & Policy, Neurology Patient Value Unit
Vifor Pharma
Medical Affairs Director
ViiV Healthcare
Director of Medical Affairs
Vynamic
Executive
Vynamic
Director
Within3
Senior Vice President, Business Partnerships
Within3
Senior Director of Business Partnerships
Zealand Pharma
Senior Project Director

EVENT TESTIMONIALS

"Highly recommended for both starters in Medical Affairs and more experienced Medical Affairs colleagues to learn about new developments in Excellence and taking Leadership in Medical Affairs roles"
Head Medical Affairs, Global Medical and Scientific Affairs CPS
Roche Diagnostics
 

“The MedAffairs Leaders Forum brought together managers from pharma/biotech and representatives from patient organizations, regulators, and service providers. In a professional, yet informal setting, valuable insights and best practices shared. Anticipating future trends was highly inspirational facilitating innovative thinking. I took important learnings, ideas, and contacts from the meeting allowing me to put new approaches into practice.”
Senior Manager, Medical Communications,
Amgen
 

“Great experience of networking with international peers from Pharma, academics and partners! I've really appreciated presentations and round tables of experts in Med Affairs area.”
Medical Education and Digital Manager
Novartis

 
"The value of going to this event relies on learning what other companies are doing, be inspired by other perspectives or ideas and take the best parts"
Head of Head of Medical Communications
Straumann

Related Videos

Presentation

Translating insights into content

Related topics: Medical Affairs & Stakeholder Engagement
Availability: FREE
  • Effectively 
  • Efficiently
  • Responsibly 
Speaker

Tessa Pugh

CEO
PharmaReview

Presentation

Maximising the omnichannel ecosystem for medical affairs

Related topics: Medical Affairs & Stakeholder Engagement, Digital & Technology
Availability: FREE
  • Ensuring accurate KOL ID for engagement
  • Utilising engagement channels for optimal outcomes
  • Connecting data to verify understanding & strategy
Speaker

Nina Levin

Vice President - Client Success
Within3

Pricing & Registration

3 Day Delegate Pass
period. prices until 17.08.2022!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
2,092 EUR
After 25% discount
2 Delegates
1,395 EUR
After 50% discount
3 Delegates
1,395 EUR
After 50% discount
4+ Delegates
1,395 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,790 EUR
2 Delegates
2,511 EUR
After 10% discount
3 Delegates
2,371 EUR
After 15% discount
4+ Delegates
2,232 EUR
After 20% discount
Academic
1 Delegate
1,150 EUR
2 Delegates
1,150 EUR
3 Delegates
1,150 EUR
4+ Delegates
1,150 EUR
2 Day Delegate Pass
period. prices until 17.08.2022!
Prices shown per delegate
1 Delegate
2 Delegates
3 Delegates
4+ Delegates
Corporate (Pharma / MedTech / BioTech)
1 Delegate
1,717 EUR
After 25% discount
2 Delegates
1,145 EUR
After 50% discount
3 Delegates
1,145 EUR
After 50% discount
4+ Delegates
1,145 EUR
After 50% discount
Solution Provider/Consultant
1 Delegate
2,290 EUR
2 Delegates
2,061 EUR
After 10% discount
3 Delegates
1,946 EUR
After 15% discount
4+ Delegates
1,832 EUR
After 20% discount
Academic
1 Delegate
950 EUR
2 Delegates
950 EUR
3 Delegates
950 EUR
4+ Delegates
950 EUR

Upgrade your Attendance to become a Member!

(Only available for corporate registrations)

Upgrade to Silver Member (Add €199 to your current registration) and receive:
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300 more added annually!
  • Be recognized at our events for your loyalty.
  • Normally valued at €999
Upgrade to Gold Member (Add €999 to your current registration) and receive:
  • Free Event Pass - Attend an additional (one) Evidence Life Science Event (in the 12 month period from your event’s dates). Just inform your Evidence Life Science representative which event!
  • Video Library Access - Receive a 12 month video library subscription (Access to over 1000 Expert Presentations from our portfolio of events, searchable & viewable on demand with 300+ videos added annually!
  • Be recognized at our events for your loyalty.
  • Normally valued at over €3780

For more information click here to learn more: https://www.evidencelifescience.com/membership